Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

Michael O. Daines, MD, division chief of Pediatric Allergy and Immunology at the University of Arizona College of Medicine and principal investigator of the phase 3 trial evaluating Panzyga for ...

John Browning, MD, highlights why pediatricians should feel comfortable prescribing recent non-steroidals, and what questions to ask patients in office. John Browning, MD, Chief of Dermatology at ...

Addictive use of screens—not total time—was linked to higher risks of suicidal behavior and mental health issues in early adolescents. A large cohort study published in JAMA has found that both high ...

On June 18, Biogen announced the dosing of participants in the BRAVE study (NCT06953583), a global phase 3 clinical trial evaluating omaveloxolone (Skyclarys) in children aged 2 to younger than 16 ...

On June 18, 2025, the FDA approved Gilead Sciences' lenacapavir (Yeztugo), an injectable HIV-1 capsid inhibitor, indicated as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired ...

The American Academy of Pediatrics (AAP) has issued updated guidance calling for pediatricians to take a comprehensive, adolescent-centered approach when providing contraceptive care. The policy ...

Case A previously healthy 10-year-old female presented to the primary care pediatric office with complaints of new onset headaches that were localized to the left side of her forehead and the left ...

A session of the American College of Obstetricians and Gynecologists 2021 annual meeting pointed to the dramatic increase in sexually transmitted infections (STIs) in the United States and presented ...

This episode focused on the most pressing unmet needs in RSV prevention and the clinical impact of newly approved options. Tan highlighted a key issue from the initial rollout of nirsevimab: supply ...

As RSV prevention tools expanded, clinicians faced new decisions around allocation, coordination, and outreach. In the final installment of this 3-part HCP Live Network RX Review roundtable, moderator ...

The FDA has accepted a new drug application (NDA) for epinephrine sublingual film (Anaphylm; Aquestive Therapeutics) to treat type 1 allergic reactions, including anaphylaxis. With the acceptance of ...